Clinical Trial

Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention

Study acronym: AMPACT
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated April 22, 2026 (before its estimated May 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Primary objective of the study is to evaluate the impact of adenosine pre-medication on incidence of slow flow/no-reflow after primary percutaneous coronary intervention.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-10.
Trial Details
NCT Number NCT07536802
Lead Sponsor National Institute of Cardiovascular Diseases, Pakistan
Conditions ST-Segment Elevation Myocardial Infarction (STEMI), No-Reflow Phenomenon, Coronary Slow Flow, Acute Myocardial Infarction
Enrollment 1,148 participants
Start Date 2025-06-01
Primary Completion 2026-05-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-22